Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M |
| Total Depreciation and Amortization | 87.00K | 90.00K | 89.00K | 81.00K | 76.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.08M | 1.83M | 1.17M | 1.15M | 1.01M |
| Change in Net Operating Assets | -1.22M | 2.69M | -1.86M | -1.50M | 846.00K |
| Cash from Operations | -11.85M | -9.45M | -11.64M | -8.74M | -6.13M |
| Capital Expenditure | 0.00 | -28.00K | -83.00K | -229.00K | -71.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 3.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.00M | 18.67M | 0.00 | -78.32M | 5.00M |
| Cash from Investing | 24.00M | 18.64M | -83.00K | -78.54M | 4.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -551.00K | -826.00K | -826.00K |
| Issuance of Common Stock | 64.00K | 6.00K | -- | 93.93M | -- |
| Repurchase of Common Stock | -- | -- | -74.00K | -- | -47.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -64.00K | 50.00K | -119.00K | -- | -- |
| Cash from Financing | 0.00 | 56.00K | -744.00K | 93.11M | -873.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.16M | 9.25M | -12.46M | 5.82M | -2.07M |